Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.38 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3415840 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL583320 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL1149470 | 0.98 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL8209880 | 0.97 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Bromide SCHEMBL583318 | 0.97 | SIGMAR1 (0.47) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL4134315 | 0.96 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL649131 | 0.96 | SIGMAR1 (0.50) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL23320287 | 0.95 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| Hydrochloric Acid SCHEMBL980555 | 0.95 | SIGMAR1 (0.49) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 | |
| SCHEMBL7044717 | 0.94 | SIGMAR1 (0.43) | SIGMAR1CHRM3CHRM5PLA2G10PLA2G5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3959208-B1 | CYCLEN BASED COMPOUNDS, COORDINATION COMPOUNDS, PEPTIDES, PHARMACEUTICAL PREPARATION, AND USE THEREOF | USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) | 2023-07-05 | — | — | EP | disclosed |
| EP-1641770-A4 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | UNIV HONG KONG (CN) | 2008-12-31 | — | — | EP | disclosed |
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | PARK FUNDING, LLC | 2007-05-10 | — | — | US | disclosed |
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | PARK FUNDING, LLC | 2007-05-10 | — | — | US | disclosed |
| EP-1641770-A1 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | The University of Hong Kong (CN) | 2006-04-05 | — | — | EP | disclosed |
| US-20050033106-A1 | Synthesis of tris N-alkylated 1,4,7,10-tetraazacyclododecanes | UNIVERSITY OF HONG KONG (CN) | 2005-02-10 | — | — | US | disclosed |
| WO-2005003105-A1 | SYNTHESIS OF TRIS N-ALKYLATED 1,4,7,10-TETRAAZACYCLODODECANES | THE UNIVERSITY OF HONG KONG (CN) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070104645-A1 | Chelate based scaffolds in tumor targeting | ITGB3, ITGB1, ITGA2B | SIGMAR1 924/4885CHRM3 2050/4885CHRM5 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.